A new comprehensive review suggests that screening men for prostate cancer using a blood test could reduce deaths from the disease, though experts continue to highlight significant risks associated with overdiagnosis and unnecessary treatment.
The findings, which analysed data from nearly 800,000 patients, are prompting a renewed discussion around the use of the prostate specific antigen (PSA) test, despite researchers acknowledging its "imperfect" nature.
